Clinical Trials
27 trialsRadical RADiotherapy and Immunotherapy for Metastatic CAncer of the Lung (RRADICAL)
Stanford University
ARIS
Hopitaux Prives de Metz, Groupe UNEOS
ROOT
Taproot Health
Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay
University of Washington
Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission
Eastern Cooperative Oncology Group
Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma
AIDS Malignancy Consortium
Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors
Eastern Cooperative Oncology Group
Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer
National Cancer Institute (NCI)
GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)
S0212 Celecoxib in Treating Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix
SWOG Cancer Research Network
Monoclonal Antibody Plus Cyclophosphamide in Treating Patients With Metastatic Cancer
National Cancer Institute (NCI)
Antineoplaston Therapy in Treating Women With Advanced Breast Cancer
National Cancer Institute (NCI)
Antineoplaston Therapy in Treating Patients With Colon Cancer
National Cancer Institute (NCI)
Antineoplaston Therapy in Treating Patients With Mantle Cell Lymphoma
National Cancer Institute (NCI)
Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy
National Cancer Institute (NCI)
Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer
National Cancer Institute (NCI)
Methotrexate With or Without Antineoplaston Therapy in Treating Postmenopausal Women With Advanced Refractory Breast Cancer
National Cancer Institute (NCI)
Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma
National Cancer Institute (NCI)
Fluorouracil, Semustine, and Vincristine Compared With BCG in Treating Patients With Dukes' B or Dukes' C Colon Cancer That Has Been Removed By Surgery
National Cancer Institute (NCI)
Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia
National Cancer Institute (NCI)
Celecoxib in Preventing Skin Cancer
National Cancer Institute (NCI)
Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
NHL
Cambridge Antibody Technology
Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease
Cambridge Antibody Technology
Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease
Cambridge Antibody Technology
IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma
GammaCan